Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)

  title={Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)},
  author={Melissa A Deri and Shashikanth Ponnala and Brian M. Zeglis and G{\'a}bor Pohl and J. J. Dannenberg and Jason S. Lewis and Lynn C. Francesconi},
  journal={Journal of Medicinal Chemistry},
  pages={4849 - 4860}
Zirconium-89 is an effective radionuclide for antibody-based positron emission tomography (PET) imaging because its physical half-life (78.41 h) matches the biological half-life of IgG antibodies. Desferrioxamine (DFO) is currently the preferred chelator for 89Zr4+; however, accumulation of 89Zr in the bones of mice suggests that 89Zr4+ is released from DFO in vivo. An improved chelator for 89Zr4+ could eliminate the release of osteophilic 89Zr4+ and lead to a safer PET tracer with reduced… 

p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.

In vivo studies demonstrate the successful use of (89)Zr-HOPO-trastuzumab to image BT474 breast cancer with low background, good tumor to organ contrast, and, importantly, very low bone uptake.

Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability

The synthesis and evaluation of novel chelating agents for zirconium-89 (89Zr) with positron emission tomography (PET) imaging applications are reported and NODHA was found to form stronger bonds with Zr(IV) when compared to NOTHA and N ODHA-PY, and NodHA-NODHA showed the highest stability in human serum without losing 89Zr.

Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for 89Zr4+ and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice

The newly developed 3-hydroxypyridin-2-one based di-macrocyclic chelator provides a viable alternative to DFO-based heterobifunctional ligands for preparation of 89Zr-labeled monoclonal antibodies for immunoPET studies.

Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry.

In this study, a new octadentate chelator is designed, synthesized, and characterized, which is an improved derivative of the previously published dodecadentates chelator DFO2, and revealed that DFO-Em has a comparable radiolabeling profile to the gold standard chelation DFO.

The Radiopharmaceutical Chemistry of Zirconium-89

This chapter provides a general overview of zirconium-89, specifically its chemical properties, production, radiochemistry, and biomedical applications and several examples of new chelators for 89Zr are discussed along with their strengths and weaknesses compared to DFO.

Side-by-Side Comparison of Five Chelators for 89Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability

Five different chelating agents, namely DFO, CTH-36, DFO*, 3,4,3-(LI-1,2-HOPO) and DOTA-GA, were compared with regard to the relative kinetic inertness of their corresponding 89Zr complexes to evaluate their potential for in vivo application and stable 89ZR complexation.

Evaluation of the Tetrakis(3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium(IV): Thermodynamic Solution Studies, Bifunctionalization, and in Vivo Assessment of Macromolecular 89Zr-THPN-Conjugates.

It is demonstrated how HPG can be used as a robust carrier tool to assess and compare the long-term in vivo stability of radiochelates and inform the design of next generation 3,4-HOPO chelates with the aim of improving the physiologic stability.

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator

The synthesis of an acyclic N-hydroxy-N-methyl succinamide-based chelator (4HMS) with 8 coordination sites and the first investigations into the use of this new chelator for 89Zr complexation are reported, making 4HMS a promising chelation system for future development of 89ZR-radiopharmaceuticals.

89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry

The most recent developments in 89Zr radiochemistry are described, including novel chelators and site-specific conjugation methods.

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab

Even though the zirconium-89 conjugates exhibited a high binding affinity for MSLN, they showed a higher tumor and lower femur uptake than [89Zr]Zr-3,2-HOPO-MSLN-mAb, and imaging results concurred with the biodistribution studies.



A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

A practical guide to the construction of radiometal-based PET bioconjugates, in which the design choices and synthetic details of a wide range of biomolecular tracers from the literature are collected in a single reference.

Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO.

Nine HOPO ligands, promptly injected or given orally or injected at low dosage, are superior to CaNa3-DTPA for reducing 238Pu retention in mouse and the most efficacious ligand, 3,4,3-LI(1,2-HOPO), contains the less stably binding 1, 2-HopO group, which must confer advantages for Pu(IV) binding.

Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

The similar biodistribution and the favorable imaging characteristics make (89)Zr a promising candidate for use as a positron-emitting surrogate for (90)Y, and an excellent correlation was found between image-derived tumor uptake data and gamma-counter values of excised tumors.

89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo

It is demonstrated that 89Zr-DFO–labeled mAbs show exceptional promise as radiotracers for immunoPET of human cancers and can be used to delineate and quantify PSMA-positive prostate tumors in vivo.

Matching chelators to radiometals for radiopharmaceuticals.

This article is a guide for selecting the optimal match between chelator and radiometal for use in these systems, and a large selection of the most common and most promising chelators are evaluated and discussed for their potential use with a variety of radiometals.

Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography

89Zr-Zevalin-PET might be well suited for prediction of 90Y-ZEValin biodistribution in a myeloablative setting, implying that 89Zr+Zr can be used as a PET surrogate label for quantification of 90 Y-ibritumomab tiuxetan biodist distribution and dosimetry before myelooblative radioimmunotherapy.

Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients

89Zr immuno-PET can be safely used to quantitatively assess biodistribution, uptake, organ residence times, and radiation dose, justifying its further clinical exploitation in the detection of tumors and planning of mAb-based therapy.

The next generation of positron emission tomography radiopharmaceuticals in oncology.

The topics covered in this review include labeling methods, biological targets, and the most recent preclinical or clinical data of some of the next generation of PET radiopharmaceuticals.